Drugs / Cannabis based medicine extract
Cannabis based medicine extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00238550 | Oct 2003 → Mar 2006 | diabetic neuropathy, neuropathy, painful | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03690791 Comparator | Jan 2019 → Dec 2023 | amyotrophic lateral sclerosis | Gold Coast Hospital and Health Service | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cannabis-based medicine extract | “The investigational product will be a cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration.” PMID 31719072 ↗ Nov 2019 |
| Known as | CBME | “The investigational product will be a cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration.” PMID 31719072 ↗ Nov 20191“Cannabis based medicine extract (CBME)” NCT00238550 ↗ |
| Known as | MediCabilis CBD Oil | “This is a randomised, double-blind, placebo controlled study on a cannabis-based medicine extract (MediCabilis CBD Oil), in patients with Amyotrophic Lateral Sclerosis or Motor...” NCT03690791 ↗ |